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The Editorial on the Research Topic
Orphan GPCRs As Emerging Drug Targets
G protein coupled-receptors (GPCRs) have been proven to be themost successful class of druggable
targets in the human genome. In fact, 30–50% of marketed drugs are estimated to exert their
clinical effects via GPCRs. Furthermore, the pace of GPCR-targeted newmolecular entities (NMEs)
approved by the US Food andDrug Administration (FDA) in the recent years still remains to a level
near its historical average, with five in 2010, five in 2011, seven in 2012, six in 2013, and eight in
2014. Out of total 219 NMEs approved by the FDA from 2005 to 2014, 54 (25%) target GPCRs.
GPCRs are and continue to be one of the most popular target classes for drug discovery. This
is in part due to the involvement of GPCRs in regulating a wide range of human physiological and
pathophysiological processes, and in part due to the fact that current GPCR drugs only target ∼80
known receptors, about 10% of all GPCRs encoded in the human genome. Efforts in elucidating
the structure, biology, and therapeutic effects of remaining GPCRs, in particular ∼140 orphan
receptors whose natural ligands are mostly unknown, shall continue to fuel the interest in GPCR
based drug discovery. Given the tremendous progresses in exploiting the chemical and biological
spaces of many orphan GPCRs, we thought to promote a Research Topic with the contribution of
top-leading scientists from both academic and industrial laboratories who have been active in the
field of translational research of orphan GPCRs.
Ichimura et al. review the molecular pharmacology, biology, and potential clinical applications
of free fatty acid receptors (FFARs). FFARs consist of four family members. Short-chain fatty acids
that contain fewer than six carbons activate FFAR3 and FFAR2, while fatty acids that contain
more than six carbons activate both FFAR1 and FFAR4. Fatty acids are both energy source and
signaling molecules that regulate energy metabolism and other physiological processes. FFARs
represent promising targets for developing innovative drugs to treat metabolic disorders associated
with dysfunction of energy balance, such as obesity, type 2 diabetes, and inflammatory bowel
disease. Although the FFAR1 agonist fasiglifam phase III trial for the treatment of type 2 diabetes
discontinued due to liver toxicity, several clinical trials targeting FFARs are still ongoing.
Thurmond reviews the discovery, molecular pharmacology, function, and clinical data of
histamine H4 receptor. The discovery of four histamine receptors is a result of almost 100 years
long endless efforts. Both H1 and H2 receptors were discovered based on clinical pharmacology
and ligand binding, while the H3 receptor was first proposed based on pharmacology and later
confirmed using a reverse pharmacology approach. In contrast, H4 receptor was discovered with
an orphan GPCR gene sequence followed by pharmacology characterization. Literature mining
of histamine activities unrelated to the other three histamine receptors suggests that H4 ligands
may be useful to treat asthma and chronic pruritus associated with conditions such as atopic
dermatitis. Animal models suggested a role for the H4 receptor in mediating pruritic responses,
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and lung function and inflammation. The H4 antagonist JNJ
39758979 has recently been found to have efficacy in preclinical
models of pruritus, dermatitis, asthma, and arthritis. Several
other H4 antagonists have also been entered into clinical trials
for these indications.
Sun and Liu review the de-orphanization, molecular
pharmacology, and biology of EBI2 (GPR183). 7α,25-
dihydroxyxcholesterol, an oxysterol, was identified to be the
likely physiological ligand of EBI2. EBI2 has been implicated in
regulating migration, activation, and functions of B cells, T cells,
dendritic cells, monocytes/macrophages, and astrocytes. EBI2
may represent a promising target for therapeutic interventions
to treat diseases associated with dysregulation of the synthesis or
functions of oxysterols.
Divorty et al. review the molecular pharmacology, signaling,
function, and therapeutic potential of GPR35. Several
endogenous molecules including kynurenic acid, cGMP,
DHICA, reverse T3, and CXCL7 can activate GPR35; however,
none has yet been confirmed to be the true endogenous agonist
for the receptor. Both endogenous and synthetic agonists
identified were found to display biased agonism and species
selectivity. Genome-wide association and functional studies
suggest that GPR35 is associated with a wide range of diseases,
such as inflammatory bowel disease, type 2 diabetes, coronary
artery disease, heart failure and hypoxia, inflammation, pain
transduction, and synaptic transmission.
Shore and Reggio review the molecular pharmacology,
expression patterns, potential clinical applications of both
GPR35 and GPR55. The authors augment that GPR35 is the
CXCR8, since it appears bind to the chemokine CXCL17
with nanomolar affinity. GPR35/CXCR8 has been implicated
in numerous pathologies involving the gastrointestinal tract,
adrenal glands, lung, uterus, liver, immune system, bladder,
kidney, bone, central nervous system, and cardiovascular system.
On the other hand, GPR55 has been recently deorphanized to
be a receptor for lysophophatidylinositol. Other GPR55 ligands
identified so far are neither cannabinoids nor bind to the
cannabinoid CB1 and CB2 receptors. GPR55 has been implicated
in three therapeutic areas, including the regulation of energy
intake and expenditure, resorption of bone, and agonist pro-
carcinogensis.
Smith reviews the expression patterns, molecular
pharmacology, and therapeutic potentials of GPR37 and
GPR37L1, the two endothelin B receptor-like receptors. Head
activator is the most likely physiological agonist for GPR37,
while the neuropeptides prosaposin and prosaptide also appear
to activate both GPR37 and GPR37L1. However, these pairings
are yet to be universally acknowledged. Both receptors are widely
expressed in the brain. GPR37 has been implicated in Parkinson’s
disease and parkinsonism, while GPR37L1 deletion leads to
precocious cerebellar development and hypertension.
Stockert and Devi review the recent progress in GPCR
structure determination and structure-based virtual screening for
identifying ligands for orphan receptors. Advances in protein
crystallography have led to the determination of over 120 X-ray
structures of GPCRs, some of which are ligand bound. These
structures can serve as templates to develop homology models
of orphan GPCRs, which, in turn, can be used to virtually screen
ligands for these receptors. Success has been made to discover
novel potent ligands for the H4 receptor, FFAR1, and several
other orphan GPCRs. The structure based approach holds great
promise in drug discovery targeting orphan GPCRs.
Altogether, the topic covers the molecular pharmacology,
biology, and potential clinical applications of several orphan
GPCRs including FFARs, H4 receptor, EIB2, GPR35, GPR55,
GPR37, and GPR37L1. In addition, structure-based virtual
screening emerged as an exciting approach to facilitate drug
discovery for orphan GPCRs.
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